Biosimilars for chronic plaque psoriasis: a 2026 update.

Authors

Martina Maurelli, Andrea Danese, Paolo Gisondi, Giampiero Girolomoni

Published in

Expert review of clinical pharmacology. Apr 29, 2026. Epub Apr 29, 2026.

Abstract

Biosimilars have emerged as a key strategy to improve access to biologic therapies in moderate-to-severe psoriasis, addressing long-standing limitations related to treatment costs and availability.
This narrative review summarizes the current evidence on biosimilars approved for psoriasis, including tumor necrosis factor inhibitors and ustekinumab, focusing on efficacy, safety, interchangeability, and pharmacoeconomic impact. A literature search was conducted in PubMed/MEDLINE and Embase to identify relevant clinical trials, real-world studies, and pharmacoeconomic analyses published between January 2015 and January 2026. Available data consistently demonstrate that biosimilars are highly similar to their reference biologics, with no clinically meaningful differences in efficacy, safety, or immunogenicity. Pharmacoeconomic studies across Europe confirm substantial cost savings and reduced cost-per-responder, supporting broader and earlier access to biologic therapy.
Biosimilars should be considered as first-line biologic options when appropriate, not only as cost-saving alternatives. Their wider use may enable earlier intervention, potentially reducing long-term disease burden and improving health system sustainability.

PMID:
42054231
Bibliographic data and abstract were imported from PubMed on 30 Apr 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.